Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments
Lambert C, Hussain T, Peters J, Longbrake E. Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments. Multiple Sclerosis And Related Disorders 2024, 94: 106236. PMID: 39755026, PMCID: PMC11869388, DOI: 10.1016/j.msard.2024.106236.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexAnti-CD20 medicationsDisease-modifying treatmentsDMT useS1P modulatorsImmunomodulatory treatmentImmune cellsSevere infectionsMultiple sclerosisLong-term immunomodulatory treatmentReal-life practice patternsTreatment durationInfection rateSelection of patientsClinical selection of patientsDeplete immune cellsObservational cohort studyBody mass indexSevere infection rateAnalyzed medical recordsIncreased infection riskInfection riskDisease modifying therapiesMultiple sclerosis patientsImmune subsetsAppointment non-attendance is associated with disease modifying therapy persistence the following year
Gromisch E, Turner A, Leipertz S, Beauvais J, Haselkorn J. Appointment non-attendance is associated with disease modifying therapy persistence the following year. Multiple Sclerosis And Related Disorders 2024, 92: 106179. PMID: 39571216, DOI: 10.1016/j.msard.2024.106179.Peer-Reviewed Original ResearchAppointment non-attendanceNon-attendanceElectronic health record dataVeterans with MSHealth record dataDisease modifying therapiesHealthcare providersNon-attendance behaviorInitial disease modifying therapiesMultiple sclerosisRecord dataLogistic regressionAppointmentProportion of NSNon-persistenceAssociated with non-persistenceVeteransTime frameDemographicsData repositoriesYearsPersonsHealthcareModifying therapiesProportionShifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
O’Donovan A, Gorelik S, Nally L. Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies. Frontiers In Endocrinology 2024, 15: 1477101. PMID: 39568817, PMCID: PMC11576206, DOI: 10.3389/fendo.2024.1477101.Peer-Reviewed Original ResearchDisease modifying therapiesStages of T1DFood and Drug AdministrationType 1 diabetesLong-term insulin dependenceDestruction of pancreatic beta cellsModifying therapiesDiagnosis of type 1 diabetesClinical diagnosis of T1DClinical diseasePathogenesis of T1DDetection of autoantibodiesDiagnosis of T1DNarrative reviewSymptoms of hyperglycemiaPancreatic beta cellsMechanism of actionAutoimmune conditionsInsulin-DependentPublished trialsGlycemic changesDrug AdministrationInsulin deficiencyTherapyClinical diagnosis154VP Usage of disease modifying therapies in spinal muscular atrophy and existing disparities: a population-based study from the MDA MOVR database
McLaren N, Joo D, Nowak R, Roy B. 154VP Usage of disease modifying therapies in spinal muscular atrophy and existing disparities: a population-based study from the MDA MOVR database. Neuromuscular Disorders 2024, 43: 104441.589. DOI: 10.1016/j.nmd.2024.07.598.Peer-Reviewed Original ResearchDisease modifying therapiesSpinal muscular atrophySurvival motor neuron 1Muscular Dystrophy AssociationModifying therapiesMuscular atrophyWhite Caucasian patientsSpinal muscular atrophy typesType 1 SMAType 2 SMALife saving therapyAlpha motor neuronsPopulation-based studyGroup of inherited neurodegenerative disordersCaucasian patientsZolgensmaNeuron 1Type 3 SMASpinal cordMuscle atrophyNusinersenPatientsTherapyMotor neuronsRisdiplam
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply